Summit Therapeutics PLC (ADR) (NASDAQ:SMMT): Alex Snow’s Lansdowne Partners filed an amended 13D.
You can check out Lansdowne Partners’ latest holdings and filings here.
Please follow Lansdowne Partners (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Lansdowne Partners or update its stock holdings.
Follow Alex Snow's Lansdowne Partners
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Lansdowne Partners (UK) L | 0 | 19,060,500 | 0 | 19,060,500 | 19,060,500 | 25.91% |
| Lansdowne Developed Markets Master Fund Limited | 0 | 19,060,500 | 0 | 19,060,500 | 19,060,500 | 25.91% |
Follow Alex Snow's Lansdowne Partners
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 8 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13D/A
Amendment No. 3
INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULES 13d-1 (a) AND
AMENDMENTS THERETO FILED PURSUANT TO
13d-2 (a)
| Summit Therapeutics PLC |
| (Name of Issuer) |
| American Depositary Shares and Ordinary Shares, par value £0.01 per share |
| (Title of Class of Securities) |
| 86627R102 |
| (CUSIP Number) |
| Hugh Orange c/o Lansdowne Partners (UK) LLP 15 Davies Street London W1K 3AG England 44-20-7290-5500 |
| (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
| December 29, 2017 |
| (Date of Event Which Requires Filing of this Statement) |
Follow Summit Therapeutics Inc. (NASDAQ:SMMT)
Follow Summit Therapeutics Inc. (NASDAQ:SMMT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 8
